This is a preview of subscription content, log in via an institution to check access.
Reference
Teitelbaum AH, et al. Treatment patterns and costs in second-line (2L) metastatic colorectal cancer (mCRC). 2013 Gastrointestinal Cancers Symposium : abstr. 544, 24 Jan 2013.
Rights and permissions
About this article
Cite this article
Costs lower for second-line bevacizumab than cetuximab in CRC. PharmacoEcon Outcomes News 673, 4 (2013). https://doi.org/10.1007/s40274-013-0199-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0199-7